Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.3 (market cap $4.03B), while Zimmer Biomet Holdings Inc trades at $93.39 (market cap $17.50B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.3× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| INDV | ZBH | |
|---|---|---|
Market Cap | $4.03B | $17.50B |
Volume | 2,781,171 | 1,890,029 |
Sector | Health | Health |
52-Week High | $41.83 | $103.98 |
52-Week Low | $24.09 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $4.32B | $24.57B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $92.08, showing modest daily movement with a slight 0.1% decline. The stock maintains a bullish technical outlook with strong moving average signals, though RSI levels indicate potential overbought conditions near-term. Fundamentally, the company demonstrates consistent revenue growth with Q2 2026 earnings beating estimates at $2.07 per share, while maintaining healthy gross margins of 69.87%. Recent corporate developments include leadership promotions in the Americas region and a declared quarterly dividend of $0.24 per share.
ZBH presents a balanced investment case with analyst consensus pointing to 12% upside to the $103.11 price target. The medical technology leader benefits from steady procedure demand and product adoption, though investors face risks from elevated debt levels and competitive pressures. With 40% of analysts rating the stock a Buy and institutional ownership expanding, the outlook remains positive despite margin compression concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
